Inclusion Criteria:

Phase 1 Specific Patient at least 18yrs of age with histologically confirmed CLL/SLL or
B-cell Non-Hodgkin lymphoma (DLBCL, FL, MCL, MZL, lymphoplasmacytic lymphoma).

Phase 2a Inclusion

   - Histological evidence: FL Grade 1-3A/iNHL, with relapsed or refractory disease (iNHL
   includes LPL/WM, MZL); aNHL, defined as DLBCL, FL Grade 3B, MCL, and transformed NHL
   with relapsed disease; CLL/SLL, PTCL, or CTCL (with MF/SS) with relapsed or
   refractory.

   - Received BCR and/or BCL2 inhibitors were intolerant or had relapsed/refractory disease
   afterwards.

   - Prior treatment for lymphoid malignancy for progressive /refractory disease

   - ≥ 1 prior regimen (min 2 cycles) with antibody conjugate, cytotoxic chemotherapy, or
   TKI alone or in combination.

   - Measureable disease defined as: ≥ 1 lesion ≥ 1.5 cm single dimension via CT, CT/PET
   with nodal or mass lesions; Quantifiable circulating tumor cells; or for Waldenström's
   macroglobulinemia presence of IgM l > 2X ULN; For CTCL: mSWAT > 0

   - Ability to provide diagnostic reports

General Inclusion

   - ECOG Score of 0 or 1.

   - Hematologic ANC > 1000/uL and platelet > 75,000/uL,

   - Serum creatinine of < 1.5 ULN or calculated CrCl of > 50 mL/min

   - Bilirubin < 20.0mg/dL (if Gilberts then < 2.5 mg/dL) and AST/AST < 2.5 ULN

Exclusion Criteria:

   - Richter's syndrome, Burkitt's lymphoma, or Burkitt-like Lymphoma (transformed DLBCL
   from Follicular NHL are eligible).

   - Prior transplant with stem cell infusion 90 days or active graft-versus-host treatment
   within 8 weeks of Day 1.

   - Prior therapy with SYK inhibitors.

   - Chronic treatment with strong CYP3A4 inhibitor/ inducer, acid reducing agent, Proton
   pump inhibitors

   - Known lymphomatous involvement of the CNS.

   - Persistent, unresolved NCI CTCAE v4.0 ≥ Grade 2, previous drug-related toxicity
   (except alopecia, erectile impotence, hot flashes, libido, neuropathy).

   - Prior monoclonal antibody, radioimmunoconjugate, antibody drug conjugate,
   phototherapy, radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or
   any test agent within 3 weeks or for alemtuzumab 8 weeks of Day 1.

   - For CTCL: (TSEBT) within 12 weeks, or initiation of topical steroid, nitrogen mustard,
   or topical retinoid within 2 weeks. (Stable topical ≥ 4 weeks prior to Day 1 allowed).

   - Known carrier or infection for HIV/Hep B or C. HCV ab+ must be PCR-. HBV ab+ must be
   HBsAg- or undetectable DNA

   - Active infection requiring systemic treatment,

   - Significant GI disease, previous major gastric/bowel surgery, difficulty swallowing or
   malabsorption syndrome.

   - Major surgery within 4 weeks

   - Previous malignancies within 2 yrs. unless relapse risk is small (< 5%).

   - Current use of systemic steroids >20 mg QD prednisone (or equivalent)

   - Breastfeeding or pregnant (intention to become) females or participation in other
   clinical trials